MEDFORD, NY--(MARKET WIRE)--Aug 14, 2007 -- Chembio Diagnostics, Inc. (OTC BB:CEMI.OB - News) has completed the studies required as part of a Clinical Laboratory Improvement Amendment (CLIA) waiver application for its "HIV barrel format" rapid test. Chembio has submitted this data and associated information in an amendment to its 2006 submission to the Center for Devices and Radiological Health division of the United States Food & Drug Administration (FDA). If the CLIA waiver is granted, it would expand the available market for Chembio's HIV barrel format test to include doctors' offices and clinics, as well as other hospitals and reference laboratories. This unique, self-contained rapid HIV test is FDA approved and exclusively marketed worldwide by Inverness Medical Innovations, Inc. as Clearview® COMPLETE HIV 1/2.
